View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ageas: The Saga continues. ASM International: KKR reportedly interested in ASM PT. D'Ieteren: Belron €8.1bn debt financing at better rates than expected. Elia: Challenges ahead, CEO appointment necessary. Gimv: €150-250m bond issue by Gimv controlling anchor investor WorxInvest. PostNL: Preparation letter on future of Dutch mail market sent to Parliament. Vonovia: Good progress on disposals

Christophe Chaput ... (+3)
  • Christophe Chaput
  • Florent Laroche-Joubert
  • Steven Boumans

ODDO : The recovery is only beginning and the best is yet to come

The rate cut carried out and yet to come (ECB: -125bp to -150bp to come by end-2025e) is a real driver for listed real estate and creates the conditions enabling it to outperform. In this context, we are lifting 23 target prices for the 42 stocks covered. Covivio, CTP, Merlin Properties, URW, Vonovia and Xior Student Housing are now our Top Picks. Aedifica (Outperform vs Neutral) should also benefit. Lastly, we are lowering Care Property to Neutral and SFL to Underperform. - >...

Christophe Chaput ... (+3)
  • Christophe Chaput
  • Florent Laroche-Joubert
  • Steven Boumans

ODDO : La reprise ne fait que commencer et le meilleur est à venir

La baisse de taux actée et à venir (BCE : -125 à 150 pb à venir d’ici fin 2025e) agit comme un véritable catalyseur pour l’immobilier côté et crée les conditions lui permettant de surperformer. Dans ce cadre, nous relevons 23 objectifs de cours sur 42 valeurs suivies. Covivio, CTP, Merlin Properties, URW, Vonovia et Xior Student Housing constituent désormais nos top picks. Aedifica (Surperformance vs Neutre) devrait également en bénéficier. Enfin, nous abaissons Care Property à N...

Jacob Mekhael ... (+3)
  • Jacob Mekhael
  • Michiel Declercq
  • Thomas Vranken

Life Sciences Conference 26.09.2024

This conference booklet is your guide to our Life Sciences Conference set to take place on Thursday, 26 September 2024 at our historic building at Grand Place in Brussels. This event offers the possibility to have one-on-one meetings and/or join pitch sessions with the following companies and their top management: Public: AUTOLUS | GALAPAGOS | HYLORIS | INVENTIVA | MAAT PHARMA | ONWARD MEDICAL | SEQUANA MEDICAL | UCB | ZEALAND PHARMA Private: CONFO TX | MRM HEALTH | PANTERA | SKYLINE DX

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Gimv: Infrastructure in and out. IMCD: First field trip preview

Jacob Mekhael
  • Jacob Mekhael

MaaT Pharma 1H24 update extends runway into 2Q25, MaaT013 phase 3 topl...

MaaT reported 1H24 results, which come with an extension of the company's cash runway into 2Q25 (from 1Q25) through prioritisation of resources on the key programs for MaaT013 and MaaT033, while management confirmed they are exploring all options for additional funding. In addition, the company reiterates the timeline for the topline results from the phase 3 (ARES) trial of MaaT013 in aGvHD in Europe, which continue to be expected in mid-4Q24 – we view this as an important trigger for the compan...

Guy Sips ... (+5)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Michiel Declercq
  • Wim Lewi
 PRESS RELEASE

MaaT Pharma publie ses résultats semestriels 2024 et réalise un point ...

Lyon, France--(BUSINESS WIRE)-- Regulatory news: (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers grâce à la modulation du système immunitaire, annonce aujourd’hui la publication de ses résultats financiers semestriels pour une période de 6 mois clôturée au 30 juin 2024 et réalise un point sur ses activités. « Forts des données positives présentées en avril 2024 lors du congrès de l'EBMT pour MaaT013 et du succès de not...

 PRESS RELEASE

MaaT Pharma Publishes its Half Year 2024 Results and Provides a Busine...

LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced its half year financial results for the six-month period ended June 30, 2024, and provided a business overview. “Building on the positive data for MaaT013 in April 2024 presented at the EBMT Congress, and the success of our recent fundraising, we have dedicated the first half of 2024 to pursuing recr...

Sharad Kumar S.P
  • Sharad Kumar S.P

Holdings Report - August 2024 KBCS Holdings Universe Up 0.5% Thanks To...

1M Performance - Absolute: During July'24 (1M period), the KBCS Holdings Universe posted a return of 0.5% which was mainly driven by multi-asset holdings (+1.7%) while single-asset holdings posted a negative return of -1.3%. The 3 top performers during the period were HAL Trust (+5.1%), Texaf (+2.9%), and The Infrastructure Company (TINC, +9.6%) while the 3 worst performers were Brederode (-2.8%), Solvac (-5.3%), and Whitestone Group (-7.2%). YTD Performance - Relative: On a YTD basis (as of A...

Hans D’Haese ... (+2)
  • Hans D’Haese
  • Stijn Demeester

Gimv/Model finetune post 1Q24/25 trading update/HOLD

In a 1Q24/25 trading update that was published last week, Gimv announced a continued solid portfolio performance resulting in a positive platform portfolio return of 3.5%. This has led to an improved NAV/share of €52 at end-June, to which should be added a further €0.5/share thanks to the sale of Mega International to Bizzdesign. This positive update provides some comfort for the remainder of the year. Moreover, it seems that the lull in private equity deal activity that traditionally marks summ...

 PRESS RELEASE

MaaT Pharma: Information mensuelle relative au nombre total de droits ...

LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers, publie le nombre d'actions composant son capital et le nombre total de droits de vote (articles L. 233-8 II du code de commerce et 223-16 du règlement général de l'AMF) au 31 août 2024. Place de cotation : Euronext Paris Code ISIN : FR0012634822 Site web : Date Nombre total d’actions composant le capital social ...

Roy Külter ... (+2)
  • Roy Külter
  • Steven Boumans

Care Property Invest : H1 2024 results: The last set of results from t...

>Adj. EPRA EPS outlook raised +1.5%; stable fair values - FY 2024 outlook raised +1.5%, now being adj. EPRA EPS of € 1.025 (vs €1.00-1.02 before) and the company maintains the intention to pay a gross dividend of €1.00/sh.Variations in fair value of investment properties were +0.2% for Q2 (Q1: -0.3%).Indexation (like-for-like rental growth) was 1.7%, similar to Q1 given the majority of leases having added indexation in January.EPRA LTV 46.4% (Q1 2024: 4...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ASML: Pushing the supplier break. CVC Capital Partners: In the bag. Gimv: Mega exit

Guy Sips ... (+6)
  • Guy Sips
  • Hilde Van Boxstael
  • Kristof Samoy
  • Lynn Hautekeete
  • Sharad Kumar S.P
  • Wim Lewi
Lynn Hautekeete
  • Lynn Hautekeete

Care Property Invest Results in line, guidance at higher end of the ra...

Care property invest reports results in line with our expectations. EPRA earnings came in at EUR 19.9m vs EUR 19.7m KBCSe, +1.3% YoY. The portfolio prove resilient with only -3.3% FV corrections since the FY23 peak and had a slightly upwards valuation of EUR 1.02m in 2Q24. The EPS guided is slightly increased from EUR 1.0-1.02 to EUR 1.025. In 1H24 Care Property Invest elected a new CEO, Patrick Couttenier. It also announced its inclusion in the EPRA index. These were the two main triggers for o...

Guy Sips ... (+11)
  • Guy Sips
  • Jacob Mekhael
  • Kristof Samoy
  • Lynn Hautekeete
  • Michiel Declercq
  • Sharad Kumar S.P
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi

Dynamic Top Pick List Update September 2024 –Cofinimmo & Kinepolis in;...

In this September update of our Dynamic Top Pick List we make 4 changes. •We include Cofinimmo in our Dynamic Top Pick List after our recent upgrade from Accumulate to Buy. We expect the name to outperform in a decreasing interest rate environment given its relatively high leverage and cheap valuation. We also believe the risk of a dilutive equity raise eased when the FY24 capex decreased from € 320m to € 250m. The management stays disciplined in its capex program and continues to focus on asse...

 PRESS RELEASE

MaaT Pharma annonce sa participation à des conférences investisseurs e...

LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem Therapies™ (MET)1 visant à améliorer la survie des patients atteints de cancers, annonce la présentation de deux posters lors du Congrès annuel de la « Society of Hematologic Oncology » qui se tiendra du 4 au 7 septembre 2024 à Houston, Texas aux États-Unis. MaaT Pharma annonce également que des membres de son équipe de direction participeront à trois conférences dédiées aux investisseurs en septembre. ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch